| 英語名 | 研究コード | 研究開発ステージ | 会社 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|
| Litifilimab | BIIB-059 | Phase 3 Clinical | Biogen Inc | Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic | 詳細 |
| SSGJ-626 | SSGJ-626; 626 | Phase 2 Clinical | Sunshine GuoJian Pharmaceutical (Shanghai) Co Ltd | Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic | 詳細 |
| DB-2304 | DB-2304 | Phase 2 Clinical | Duality Biologics (Suzhou) Co Ltd | Autoimmune Diseases; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic | 詳細 |
| ANB-101 | CBS-004; ANB101 | Phase 1 Clinical | Capella Bioscience Ltd | Inflammation; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic; Scleroderma, Systemic | 詳細 |
| BCD-256 | BCD-256 | Phase 1 Clinical | BIOCAD JSC | Lupus Erythematosus, Systemic | 詳細 |
| GB-19 | GB-19; GB19 | Phase 1 Clinical | Shandong Kexing Bio-Products Co Ltd | Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic | 詳細 |
| Recombinant anti-BDCA2 humanized monoclonal antibody (Sansheng Guojian) | Phase 1 Clinical | Sunshine GuoJian Pharmaceutical (Shanghai) Co Ltd | Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic | 詳細 | |
| HC-022 | HC-022; HC022 | Phase 1 Clinical | Shanghai Hongcheng Pharmaceutical Co Ltd | Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic | 詳細 |
| LBL-047 | DNTH-212; LBL-047; DNTH212 | Phase 1 Clinical | Nanjing Leadsbiolabs Co Ltd | Autoimmune Diseases; Lupus Erythematosus, Systemic | 詳細 |